Investors

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing products which reduce hunger and food cravings, enhance the gut microbiome, and sweet fibres as healthy sugar substitutes, announces the publication of a new peer-reviewed study on SlimBiome® in the European Journal of Nutrition.  The European Journal of Nutrition is a peer reviewed, international journal that has a high impact factor with its articles widely cited and influential in its field.

The double-blind placebo-controlled study, led by Adele Costabile, Professor of Clinical Nutrition and the Microbiome at the University of Roehampton, found a single 3g dose of SlimBiome significantly reduced insulin levels, hunger, and the desire to eat whilst increasing the feeling of fullness. These are key factors in appetite regulation and the study conclusion highlights the potential of SlimBiome® as a non-pharmaceutical  approach to weight management. Prof Costabile will present her findings at the  18th International Scientific Conference on Probiotics, Prebiotics, Gut Microbiota and Health being held on  24-26 June 2025.

These findings on the impact of a single dose of SlimBiome® are consistent with other published studies, consumer studies, and customer feedback which have shown SlimBiome® reduces hunger and food cravings leading to users both reducing the amount of food and the type of food they eat, leading to more sustainable weight management.

The study was carried out to support health claims for appetite regulation and hunger control in products of one of the USA's leading weight management brands (see announcement on 15 April 2025). Scientifically substantiated health claims help to differentiate SlimBiome® from other products on the market. OptiBiotix now has acute and long-term studies in healthy, overweight, and obese individuals which have allowed the Company to make on pack health claims in Europe, Australia/New Zealand, India, Asia, Canada, and the USA leading to agreements and multiple product launches with major international and national companies and brands (e.g Morepen, Muscletech, Myprotein). In the changing landscape of this market, brought about by the anti-obesity drugs, traditional approaches to weight management are being replaced by science backed products which provide functional benefits such as reduced hunger and desire to eat. SlimBiome® meets this developing trend. 

The University of Roehampton has published a press release which is set out below in Appendix I.

Stephen O'Hara, CEO of OptiBiotix Health plc commented: "We are really pleased to see this study published in such a well-respected journal.  The study adds further evidence to demonstrate the efficacy of SlimBiome® in reducing hunger and food cravings leading to changes in the amount and type of food people eat. Whilst the anti-obesity drugs have strong risk-benefits in the 16%* of the world adult population who are obese, they may not be the best choice for the 43%* who are overweight. SlimBiome® represents a natural alternative, particularly for overweight individuals, and has been widely used with no reported adverse side effects".

*See WHO report  Obesity and overweight

The Directors of the Company are responsible for the release of this announcement.

For further information, please contact:

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.